Anti-tumor activity of yeast vesicle biomimetic nanomedicine with the ability of active tumor penetration
10.16438/j.0513-4870.2021-1240
- VernacularTitle:主动渗透型酵母囊泡仿生纳米药物抗肿瘤活性研究
- Author:
Jun-jie LIU
;
Li-hua XU
;
Kai-xiang ZHANG
;
Xiu ZHAO
;
Yi-yang WANG
;
Jin-jin SHI
;
Zhen-zhong ZHANG
- Publication Type:Research Article
- Keywords:
extracellular matrix;
cell-derived microparticle;
nanomedicine;
pH sensitive;
anti-tumor activity
- From:
Acta Pharmaceutica Sinica
2022;57(1):222-232
- CountryChina
- Language:Chinese
-
Abstract:
The dense extracellular matrix (ECM) of the tumor severely limits the deep penetration of nanomedicine and weakens its anti-tumor effect. Based on this, the yeast vesicle biomimetic nanomedicine with active deep penetration ability of tumor tissue was designed and developed for enhanced tumor therapy. Results of characterization showed that the yeast cell vesicles (YCV) displayed a spherical morphology with diameter of around 100 nm and was well dispersed. Then the chemotherapeutic drug doxorubicin (DOX) was selected as a model drug, and DOX was loaded into YCV to obtain YCV/DOX through electrostatic interaction, the encapsulation efficiencies of DOX were calculated as 82.5%. The drug release profile of YCV/DOX implied that DOX release showed a manner of pH-dependent, it may be that pH has affected the electrostatic effect of YCV and DOX. Compared with liposomes (Lipo), in vitro cell experiments showed that YCV from natural sources had stronger permeability in three-dimensional multicellular spheres. It is speculated that the mechanism may be good deformation capacity of YCV. A 4T1 xenograft tumor model was established to evaluate the therapeutic efficacy of YCV/DOX. The results suggested that YCV/DOX has stronger tumor tissue penetration ability and could effectively inhibit the tumor growth. All animal experiments were performed in line with national regulations and approved by the Animal Experiments Ethical Committee of Zhengzhou University. This study brings new ideas for the development of biomimetic nanomedicine to overcome the ECM of solid tumors.
